Yuji Yasuda

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.

K. Matsushita, H. Yotsuyanagi, H. Fukase, 2012, Vaccine.

Functional Consequences of Shifting Transcript Boundaries in Glucose Starvation

Masaru Mori, L. Nguyen, J. Galipon, 2023, bioRxiv.

Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children

K. Matsushita, M. Lattanzi, R. Komatsu, 2010, Advances in therapy.